WallStSmart
BOLD

Boundless Bio, Inc. Common Stock

NASDAQ: BOLD · HEALTHCARE · BIOTECHNOLOGY

$2.53
-1.94% today

Updated 2026-10-09

Market cap
$60.05M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.85
Dividend yield
—
52W range
$1 – $3
Volume
0.2M

Boundless Bio, Inc. Common Stock (BOLD) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20162017201820212022202320242025
Operating cash flow$-49.02M$-84.51M$-107.98M$-23.25M$-39.60M$-46.85M$-60.84M$-46.66M
Capital expenditures$16.65M$7.55M$11.61M$2.03M$1.07M$633000.00$2.54M$546000.00
Depreciation————————
Stock-based comp$2.00M$6.88M$16.50M$1.16M$2.29M$3.34M$7.52M$6.13M
Free cash flow$-65.67M$-92.06M$-119.59M$-25.28M$-40.66M$-47.49M$-63.38M$-47.21M
Investing cash flow————————
Financing cash flow————————
Dividends paid————————
Share repurchases————————
Debt repayment————————
Net change in cash————————

Frequently asked questions

How much free cash flow does BOLD generate?

BOLD produced $-47.21M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is BOLD's balance sheet healthy?

BOLD holds $17.87M in cash and equivalents against — in long-term debt, on $98.65M of shareholder equity. That debt is best read against the cash flow the business throws off each year.